Loprinzi C L, Johnson P A, Jensen M
Mayo Clinic, Departments of Oncology, Rochester, MN 55905.
Oncology. 1992;49 Suppl 2:46-9. doi: 10.1159/000227128.
Based on promising preliminary information obtained from uncontrolled pilot studies, several randomized, placebo-controlled, double-blind clinical trials have been launched to evaluate the effectiveness of megestrol acetate for the treatment of patients with anorexia and/or cachexia. The results of these studies have demonstrated that megestrol acetate can improve patients' appetites and promote nonfluid weight gain in some. They also suggest that megestrol acetate has antiemetic properties. Ongoing clinical trials are evaluating the dose-response relationship of megestrol acetate for these clinical problems and whether megestrol acetate will improve the survival of patients at risk for developing cancer anorexia/cachexia.
基于从非对照试验性研究中获得的有前景的初步信息，已经开展了多项随机、安慰剂对照、双盲临床试验，以评估醋酸甲地孕酮治疗厌食和/或恶病质患者的有效性。这些研究结果表明，醋酸甲地孕酮可以改善患者食欲，并使部分患者非体液性体重增加。研究还提示醋酸甲地孕酮具有止吐特性。正在进行的临床试验正在评估醋酸甲地孕酮针对这些临床问题的剂量反应关系，以及醋酸甲地孕酮是否会提高有发生癌性厌食/恶病质风险患者的生存率。
